

Histiocytosis UK

known as

Histio UK

Annual Report and Financial Statements

for the Year Ended 31 March 2021

Histiocytosis UK

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 7
Statement of Trustees' Responsibilities	8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 to 17

Histiocytosis UK

Reference and Administrative Details

Trustees	Mr A Kontoyannis, Chair Prof. P Beverley Dr J Visser (Resigned on 07/11/2020) Dr V Nanduri Mr P Bienenstock Prof. M Collin Dr C Booth
Other Officers	Lynn Jackson, Executive Director
Principal Office	PO Box 159 Liskeard Cornwall PL14 9DQ
Charity Registration Number	1158789
Bankers	CAF Bank Limited 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ
Independent Examiner	Bulley Davey Limited Chartered Certified Accountants 33 Boston Road Holbeach Spalding Lincolnshire PE12 7LR

Histiocytosis UK

Trustees' Report

The trustees present the annual report together with the financial statements of the charity for the year ended 31 March 2021.

Objectives and activities

Public benefit

☐ The object of the CIO is the relief of sickness and preservation of good health among patients affected by histiocytic diseases their families and carers, in particular but not exclusively by:

☐ (i) the promotion and furtherance of scientific research into the physiology and pathology of histiocytes and the aetiology of histiocytotic diseases, the useful results of which will be disseminated for the public benefit;

☐ (ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases;

☐ (iii) the provision and dissemination of information, education and knowledge in support of patients and families affected by the disease to include the medical professions and general public;

☐ (iv) collaboration with interested individuals and organisations.

The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities and setting the grant making policy for the year.

The Charity carries out these objectives by focusing on these areas through which we achieve our strategic priorities of maintaining a stable programme and the continued funding of vital research.

The benefits of the Charity's work are the development of future research, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being able to inform sufferers, their carers and families.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Financial review

Investment policy and objectives

The Charity's policy at present is to invest in low-risk and reasonably liquid assets, so that funds are available to meet any unforeseen needs that may arise, for example, as a consequence of meeting activities.

As far as possible, the Charity seeks to follow an ethical investment strategy that precludes investing in any company whose activities may have an adverse impact on the underlying beneficiaries of the charity. While striving for the highest ethical standards, the Charity will adhere to the Charity Commission's rule that we maximise the income of the charity without exposure to undue risk.

Histiocytosis UK

Trustees' Report

Financial review

The Chairman regularly reviews the reserves of the charity to ensure that sufficient liquid funds are available to the Charity to meet its ongoing obligations. The reserves throughout the accounting period have been adequate to fulfil this objective.

Income & Expenditure Summary

The 2020–2021 income was greatly reduced this financial year due in the most part to the Covid 19 pandemic and public fundraising focused on the NHS Charities.

We thank our generous donors drawn from individuals, community groups, corporate supporters, Charities and Foundations that continued their support and reflects the excellent participation, drive and generosity of our community fundraisers, supporters, families and committed individuals that have been able to assist us maintain the Charity.

Grant Awards

Applications were invited for studies into the histiocytic disorder Paediatric Langerhans Cell Histiocytosis, for a maximum budget of £50,000 and duration of up to 24 months.

Histio UK considered scientific and clinical research on the epidemiology, pathogenesis, diagnosis, treatment and clinical care of patients with histiocytosis. Applicants were required to describe the likely impact of their research upon patients with histiocytosis and to outline a plan to attract further independent funding, using the award to drive forward new competitively funded research relevant to histiocytosis.

We are pleased to announce the following award was approved by the Trustees.

A UK & European multi centre project Lead By Dr Elena Sieni:-

MUTANT BRAF ALLELE BURDEN IN RELATION TO CLINICAL OUTCOME

Aim 1: bio banked and prospectively collected peripheral blood samples will be used to assess which of the two available assays (cell-free DNA isolated from plasma or DNA extracted from bulk blood cells) correctly reflects (changes in) disease burden. These results will lay the basis for a non-invasive monitoring protocol for improved clinical management of patients.
Aim 2: will analyse which type(s) of lineage cells in the blood actually express mutant BRAF alleles. This part of the project delivers data which help to further unravel the pathophysiology of LCH.

Grants Received

We are incredibly pleased to announce that during 2020 Histio UK have been successful in our application to the National Lottery Community Fund.

The funders awarded Histio UK £36,560 for our Histio Communities Project: Histio Connect - Let's Talk an inclusive on-line discussion platform for each of the different histiocytic disorders.

The platform will provide our Histio Champions the opportunity to chat, share their voices, their stories, achievements and memories enabling the opportunity to raise awareness, inspire others, learn more about other parents, patient, family's supporters and volunteers who shape this rare community.

Our Thanks to all our Histio community champions and HM Government for making this possible.

Histio UK Connect

We know that all Histio journeys come with unique challenges and we would like to hear about how we can best help you.

Can you help us try meet your needs with helpful information and programs through your histio journey?

However, you found us here at Histio UK whether you come to us newly diagnosed or have been with us for years, your input will guide us in providing the information you and many others may need in our Histio Community. Keep a look out in 2021 for our new Let's Talk & Connect Forum UK.

Histiocytosis UK

Trustees' Report

Chairman's Statement

Financial

This year has been a challenging time for the Charity and as we look back over this year's operation, we again reflect on the continued support that we have received during this unprecedented period for all. Despite reduced income we have been able to continue our Information Support services and announce a Research award of £50,000 to a UK & European multi centre project Lead By Dr Elena Sieni.

We are very pleased to have delivered various Histiocytic information guides and our outstanding community platform HistoUKConnect.org - Let's Talk programme.

In association with our partners, we will continue to support histiocytic professionals, patients and families with up-to-date information on these devastating disorders as it becomes available.

Thank you all.

Partnerships

Let's Talk-Histio UK Connect

Across Continents an Awareness Initiative for all Histiocytic disorders.

Let's Talk-Histio UK Connect - The Let's Talk Project has gathered together with Parent and Patient associations from across the continents via online discussion media.

In partnership with the USA, Canada, Greece, Italy, Spain, France, Argentina, and Brazil discussions will continue with a view to advance Patient and Parent support, information provision and knowledge sharing at local and international levels.

Hi-HASC- Haemophagocytic Lymphohistiocytosis (HLH) Across Speciality Collaboration
Histio UK continues to provide administrative support to this amazing group.

Awareness

November 2020 saw the 6th UK Histiocytosis Forum held virtually over two sessions including:

Haemophagocytic Lymphohistiocytosis

Hosted by Dr. Claire Booth

Dr Anupama Rao - Post HSCT outcomes in children with primary (genetic) HLH treated on Emapalumab.

Dr Alasdair Bamford - PIMS-TS/COVID related hyperinflammation in children.

Dr Jessica Manson - Covid 19 HLH and Hyperinflammation

Prof Joe West - Incident & Survival Population Cohort

Langerhans Cell Histiocytosis

Hosted by Prof Matthew Collin

Dr Milne - Advances in molecular diagnostics

Dr Donadieu - Targeted inhibitors

Plans for the future.

Histio UK, will remain at the forefront in challenging this devastating disease, we will continue to build on the transfer of information and knowledge available nationally and international through our committee structure to parents, patients and medical professionals.

Histiocytosis UK

Trustees' Report

Structure, governance and management

Organisational structure

Histiocytosis UK is a registered charity, number 1158789, and is constituted as a charitable incorporated organisation in England and Wales.

The Charity actively fundraises and seeks to continue the charitable work desired by the donor through the careful stewardship of its existing resources.

At the annual Trustees' meetings, the Trustees agree the broad strategy and areas of activity for the Charity, including consideration of grant making, investment, reserves and risk management policies and performance.

The day-to-day administration of grants and the processing and handling of applications prior to consideration by the Charity is delegated to the Executive Director.

The Charity's Independent Scientific Review Board consider all applications against agreed criteria prior to making recommendation to the Charity on funding grants. The SRB review all applications received in response to calls for proposals.

The Chair of the SRB for 2020-2021

Professor Matthew Collin. BM, BCh, DPhil, MRCP, FRCPath.

Vice-Chair

Professor Peter Beverley MBBS, DSc, FMedSci.

The Trustees review on a regular basis both to recruit new Trustee(s) for their experience, empathy and knowledge of the charity and to keep the skills and composition of the Trustee body and succession planning under review.

As we move into our new financial year Trustees will retire at the end of their term of office with the Charity. As always, we will take this opportunity to review our Governance structure and assess the benefits of utilising any opportunities that may be derived from advisory boards allowing us to more fully support the Executive Director in forthcoming projects and initiatives and at the same time focus on our strengths.

Sad News

Dr Johannes Visser retired from the Board of Trustees on 7th November 2020, and it is our sad duty to advise that Dr Johann Visser, died on the 20th December 2020, he was a consultant Paediatric Oncologist in Leicester and then Cambridge. Johann was a modest and gentle man and a dedicated and caring clinician, who made an enormous contribution to treatment of Langerhans Cell Histiocytosis (LCH) in the UK and world-wide.

He became a trustee of Histiocytosis UK in 2014 having previously served on the Board of Trustees at the Histiocytosis Research Trust. Johann contributed hugely to the Trust's activities with excellent, common-sense advice. He also played a major role in preparing the information booklet on Paediatric LCH that Histio UK distributes to doctors throughout the UK and in preparing material for the Histio UK website.

He worked tirelessly to improve the treatment of histiocytosis patients in the UK, setting up and running the national Histiocytosis Advisory Group. This is a computer-based forum for doctors treating histiocytosis patients. Any doctor needing advice can discuss a patient with doctors who are experts in histiocytosis, including of course Johann, at fortnightly "meetings". His clinical insight and advice will be desperately missed by everyone in the UK, who treats histiocytosis patients. Johann was also the lead investigator in the UK for the LCH IV international clinical trial. Because LCH is such a rare disease, such international trials are the only way in which new treatments can be properly assessed on enough patients to obtain reliable data. Running the trials is a laborious and time-consuming duty that Johann took on to the great benefit of all LCH patients. Recently kinase inhibitors, drugs such as Vemurafenib, that target the mutations in LCH have been developed and have raised the hope that they might revolutionise treatment of the disease. However, the introduction of any new therapy must be carefully assessed in clinical trials. Johann took part in the first international clinical trials of kinase inhibitor therapy in children, showing that these drugs may have a useful role in treatment of the disease and can be safely administered to children.

(Continued on Page 6)

Histiocytosis UK

Trustees' Report

Johann will be sorely missed by friends and colleagues throughout the UK and the international community of clinicians and scientists, who work on histiocytoses. It is a tragedy that such respected and influential figure has been taken from us at the early age of 52 years.

Fundraising Regulation

The Charity is registered with the Fundraising Regulator and is in full compliance with its requirements. The Charity adheres to the key principles and behaviours in that the work of its fundraising will be Legal, Open, Honest and Respectful.

Risk management

The Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks.

The Trustees consider variability of investment returns.

Histiocytosis UK

Trustees' Report


Our thanks

The Charity wishes to express its gratitude to all our volunteers for their fundraising activities, technical skills, and participation in virtual and physical events that have taken place throughout the country in this difficult year, special thanks to all of those that make our Lets Talk - Histiocytosis UK Connect programme such a great success.

Our thanks to our Corporate donors including those with match funding programmes which encourage our supporters with their own fundraising activities.

Our thanks to our partner Charitable Trusts, Violets In Bloom and Giddo's Gift for their support in this difficult year.

The annual report was approved by the trustees of the charity on 04/06/21 and signed on its behalf by:


Mr A Kontoyannis
Chair

Histiocytosis UK

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.

The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by the trustees of the charity on 04/06/21 and signed on its behalf by:


Mr A Kontoyannis
Trustee

Histiocytosis UK

Independent Examiner's Report to the trustees of Histiocytosis UK

I report on the accounts of the charity for the year ended 31 March 2021 which are set out on pages 10 to 17.

Respective responsibilities of trustees and examiner

The trustees are responsible for the preparation of the accounts. The trustees consider that an audit is not required for this year under section 144(2) of the Charities Act 2011 (the 2011 Act) and that an independent examination is needed.

It is my responsibility to:

- examine the accounts under section 145 of the 2011 Act;
- to follow the procedures laid down in the general Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act; and
- to state whether particular matters have come to my attention.

Basis of independent examiner's report

My examination was carried out in accordance with the general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and consequently no opinion is given as to whether the accounts present a 'true and fair view' and the report is limited to those matters set out in the next statement.

Independent examiner's statement


In connection with my examination, no matter has come to my attention:

(1) which gives me reasonable cause to believe that in any material respect the requirements:

- to keep accounting records in accordance with section 386 of the Companies Act 2006; and
- to prepare accounts which accord with the accounting records, comply with the accounting requirements of section 396 of the Companies Act 2006 and with the methods and principles of the Statement of Recommended Practice: Accounting and Reporting by Charities

have not been met; or

(2) to which, in my opinion, attention should be drawn in order to enable a proper understanding of the accounts to be reached.



Christopher McKenna ACA

Bulley Davey Limited
Chartered Certified Accountants
33 Boston Road
Holbeach
Spalding
Lincolnshire
PE12 7LR

Date:.....

Histiocytosis UK

Statement of Financial Activities for the Year Ended 31 March 2021

	Note	Unrestricted £	Restricted £	Total 2021 £	Total 2020 £
Income and Endowments from:					
Charitable activities	2	84,970	36,560	121,530	177,424
Investment income	3	91	-	91	302
Total Income		85,061	36,560	121,621	177,726
Expenditure on:					
Raising funds	4	(1,173)	-	(1,173)	(1,813)
Research grants awarded	5	(82,562)	-	(82,562)	(90,536)
Charitable activities	6	(46,995)	(36,560)	(83,555)	(74,474)
Total Expenditure		(130,730)	(36,560)	(167,290)	(166,823)
Net movement in funds		(45,669)	-	(45,669)	10,903
Reconciliation of funds					
Total funds brought forward		404,045	-	404,045	393,142
Total funds carried forward	13	358,376	-	358,376	404,045

All of the charity's activities derive from continuing operations during the above two periods.
The funds breakdown for 2020 is shown in note 13.

Histiocytosis UK

(Registration number: 1158789)
Balance Sheet as at 31 March 2021

	Note	2021 £	2020 £
Fixed assets			
Tangible assets	10	904	1,348
Current assets			
Debtors	11	686	671
Cash at bank and in hand		359,569	404,825
		360,255	405,496
Creditors: Amounts falling due within one year	12	(2,783)	(2,799)
Net current assets		357,472	402,697
Net assets		358,376	404,045
Funds of the charity:			
Unrestricted income funds			
Unrestricted		358,376	404,045
Total funds	13	358,376	404,045

The financial statements on pages 10 to 17 were approved by the trustees, and authorised for issue on 04/06/21 and signed on their behalf by:

Mr A Kontoyannis
Chair

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

1 Accounting policies

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

Histiocytosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Exemption from preparing a cash flow statement

The charity opted to early adopt Bulletin 1 published on 2 February 2016 and have therefore not included a cash flow statement in these financial statements.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the Charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Tangible fixed assets

Individual fixed assets costing £100.00 or more are initially recorded at cost.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Office equipment	33% reducing balance

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of is established when there is objective evidence that the will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees's discretion in furtherance of the objectives of the charity.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

2 Income from charitable activities

	Unrestricted		Total 2021	Total 2020
	General £	Restricted £	£	£
Donations	84,970	-	84,970	177,031
Gift aid tax reclaimed	-	-	-	393
Lottery fund	-	36,560	36,560	-
	<u>84,970</u>	<u>36,560</u>	<u>121,530</u>	<u>177,424</u>

The total income from charitable activities for the year was £121,530 (2020 - £177,424) of which £84,970 (2020 - £177,424) was attributable to unrestricted funds and £36,560 (2020 - £Nil) to restricted funds.

3 Investment income

	Unrestricted funds General £	Total 2021 £	Total 2020 £
Interest receivable and similar income;			
Interest receivable on bank deposits	<u>91</u>	<u>91</u>	<u>302</u>

The total investment income for the year was £91 (2020 - £302) of which £91 (2020 - £302) was attributable to unrestricted funds and £Nil (2020 - £Nil) to restricted funds.

4 Expenditure on raising funds

	Unrestricted General £	Total 2021 £	Total 2020 £
General fundraising and events expenses	<u>1,173</u>	<u>1,173</u>	<u>1,813</u>

The total expenditure on raising funds for the year was £1,173 (2020 - £1,813) of which £1,173 (2020 - £1,813) was attributable to unrestricted funds and £Nil (2020 - £Nil) to restricted funds.

5 Expenditure on research grants awarded

	Unrestricted funds General £	Total 2021 £	Total 2020 £
Research costs	<u>82,562</u>	<u>82,562</u>	<u>90,536</u>
	<u>82,562</u>	<u>82,562</u>	<u>90,536</u>

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

The total expenditure on research grants awarded for the year was £82,562 (2020 - £90,536) of which £82,562 (2020 - £90,536) was attributable to unrestricted funds and £Nil (2020 - £Nil) to restricted funds.

6 Expenditure on charitable activities

		Unrestricted		Total	Total
	Note	General	Restricted	2021	2020
		£	£	£	£
Trustees expenses		-	-	-	1,090
Travelling		1,333	-	1,333	8,649
Insurance		901	-	901	865
Telephone		895	-	895	1,023
Computer expenses		1,716	-	1,716	2,589
Printing, postage, stationery and advertising		3,321	-	3,321	3,298
Charitable donations		-	-	-	4,039
Accountancy fees		1,422	-	1,422	1,398
Bank charges		69	-	69	86
Depreciation		444	-	444	665
Staff costs	8	36,894	12,063	48,957	47,531
Outreach costs		-	24,497	24,497	3,241
		<u>46,995</u>	<u>36,560</u>	<u>83,555</u>	<u>74,474</u>

The total expenditure on charitable activities for the year was £83,555 (2020 - £74,474) of which £46,995 (2020 - £72,266) was attributable to unrestricted funds and £36,560 (2020 - £2,208) to restricted funds.

7 Net incoming/outgoing resources

Net (outgoing)/incoming resources for the year include:

	2021	2020
	£	£
Depreciation of fixed assets	<u>444</u>	<u>665</u>

8 Staff costs

The aggregate payroll costs were as follows:

	2021	2020
	£	£
Staff costs during the year were:		
Wages and salaries	<u>48,957</u>	<u>47,531</u>

No employee received emoluments of more than £60,000 during the year.

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

9 Taxation

The charity is a registered charity and is therefore exempt from taxation.

10 Tangible fixed assets

	Office equipment £	Total £
Cost		
At 1 April 2020	3,568	3,568
At 31 March 2021	3,568	3,568
Depreciation		
At 1 April 2020	2,220	2,220
Charge for the year	444	444
At 31 March 2021	2,664	2,664
Net book value		
At 31 March 2021	904	904
At 31 March 2020	1,348	1,348

11 Debtors

	2021 £	2020 £
Prepayments	686	671

12 Creditors: amounts falling due within one year

	2021 £	2020 £
Other taxation and social security	1,379	1,413
Accruals	1,404	1,386
	2,783	2,799

13 Funds

	Balance at 1 April 2020 £	Incoming resources £	Resources expended £	Balance at 31 March 2021 £
Unrestricted				
General	404,045	85,061	(130,730)	358,376
Restricted	-	36,560	(36,560)	-
Total funds	404,045	121,621	(167,290)	358,376

Histiocytosis UK

Notes to the Financial Statements for the Year Ended 31 March 2021

	Balance at 1 April 2019 £	Incoming resources £	Resources expended £	Balance at 31 March 2020 £
Unrestricted				
General	390,934	177,726	(164,615)	404,045
Restricted	<u>2,208</u>	<u>-</u>	<u>(2,208)</u>	<u>-</u>
Total funds	<u>393,142</u>	<u>177,726</u>	<u>(166,823)</u>	<u>404,045</u>

14 Analysis of net assets between funds

	Unrestricted funds General £	Total funds at 31 March 2021 £
Tangible fixed assets	904	904
Current assets	360,255	360,255
Current liabilities	<u>(2,783)</u>	<u>(2,783)</u>
Total net assets	<u>358,376</u>	<u>358,376</u>